The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis

被引:18
作者
Zhang, Rui [1 ]
Tian, Panwen [1 ,2 ]
Chen, Bojiang [1 ]
Wang, Tao [3 ]
Li, Weimin [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Resp & Crit Care Med, 37 GuoXue Alley, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Lung Canc Treatment Ctr, Chengdu, Sichuan, Peoples R China
[3] Zunyi Med Univ, Dept Resp & Crit Care Med, Affiliated Hosp, Zunyi, Guizhou, Peoples R China
关键词
Lung cancer; TP53; epidermal growth factor receptor; prognosis; P53; MUTATIONS; POOR-PROGNOSIS; GEFITINIB; SURVIVAL; GENE; HETEROGENEITY; CHEMOTHERAPY; RESISTANCE; INHIBITORS; KRAS;
D O I
10.1080/00325481.2019.1585690
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The prognostic value of TP53 commutation in epidermal growth factor receptor (EGFR) mutant lung cancer is controversial and we therefore conducted this systematic review and meta-analysis.Methods A systematic search was carried out in Pubmed, Web of Science, the Cochrane Library, Medline and Embase up to 19 April 2018. The pooled hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS), the relative risk (RR) of objective response rate (ORR) were calculated.Results Overall, a total of eight studies comprising 2979 patients were included. When generally comparing TP53 mutation group with TP53 wild-type group, we confirmed the prognostic value of poor OS of TP53 in EGFR mutant lung cancers (HR 1.73, 95% CI 1.22-2.44, P = 0.002). In subgroup analysis of OS, the prognostic value was maintained in patients treated with EGFR tyrosine kinase inhibitors (TKIs) but not in those treated with non-targeted therapy (HR 2.29, 95% CI 1.39-3.76, P = 0.001), and was also maintained in patients with advanced-stage lung cancers rather than those of all stages (HR 2.00, 95% CI 1.11-3.61, P = 0.021). For patients treated with EGFR TKIs, TP53 commutation was predictive of a poor PFS (HR 2.18, 95% CI 1.42-3.36, P < 0.001) but the prognostic value on ORR was not observed (RR 1.15, 95% CI 0.92-1.44, P = 0.212). Additional subgroup analysis based on TP53 mutation subtypes was not pooled due to limited data.Conclusion Generally we confirmed the prognostic value of poor OS and PFS of TP53 commutation in EGFR mutant lung cancers, and it should be further investigated and validated regarding the prognostic role of TP53 mutation subtypes.
引用
收藏
页码:199 / 206
页数:8
相关论文
共 42 条
  • [1] p53 Mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study
    Ahrendt, SA
    Hu, YC
    Buta, M
    McDermott, MP
    Benoit, N
    Yang, SC
    Wu, L
    Sidransky, D
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (13) : 961 - 970
  • [2] The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)
    Aisner, Dara L.
    Sholl, Lynette M.
    Berry, Lynne D.
    Rossi, Michael R.
    Chen, Heidi
    Fujimoto, Junya
    Moreira, Andre L.
    Ramalingam, Suresh S.
    Villaruz, Liza C.
    Otterson, Gregory A.
    Haura, Eric
    Politi, Katerina
    Glisson, Bonnie
    Cetnar, Jeremy
    Garon, Edward B.
    Schiller, Joan
    Waqar, Saiama N.
    Sequist, Lecia V.
    Brahmer, Julie
    Shyr, Yu
    Kugler, Kelly
    Wistuba, Ignacio I.
    Johnson, Bruce E.
    Minna, John D.
    Kris, Mark G.
    Bunn, Paul A.
    Kwiatkowski, David J.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (05) : 1038 - 1047
  • [3] [Anonymous], 2013, SCI TRANSL MED
  • [4] OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS
    BEGG, CB
    MAZUMDAR, M
    [J]. BIOMETRICS, 1994, 50 (04) : 1088 - 1101
  • [5] Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
    Bria, Emilio
    Pilotto, Sara
    Amato, Eliana
    Fassan, Matteo
    Novello, Silvia
    Peretti, Umberto
    Vavala, Tiziana
    Kinspergher, Stefania
    Righi, Luisella
    Santo, Antonio
    Brunelli, Matteo
    Corbo, Vincenzo
    Giglioli, Eliana
    Sperduti, Isabella
    Milella, Michele
    Chilosi, Marco
    Scarpa, Aldo
    Tortora, Giampaolo
    [J]. ONCOTARGET, 2015, 6 (14) : 12783 - 12795
  • [6] Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
    Canale, Matteo
    Petracci, Elisabetta
    Delmonte, Angelo
    Chiadini, Elisa
    Dazzi, Claudio
    Papi, Maximilian
    Capelli, Laura
    Casanova, Claudia
    De Luigi, Nicoletta
    Mariotti, Marita
    Gamboni, Alessandro
    Chiari, Rita
    Bennati, Chiara
    Calistri, Daniele
    Ludovini, Vienna
    Crino, Lucio
    Amadori, Dino
    Ulivi, Paola
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2195 - 2202
  • [7] Comprehensive molecular profiling of lung adenocarcinoma
    Collisson, Eric A.
    Campbell, Joshua D.
    Brooks, Angela N.
    Berger, Alice H.
    Lee, William
    Chmielecki, Juliann
    Beer, David G.
    Cope, Leslie
    Creighton, Chad J.
    Danilova, Ludmila
    Ding, Li
    Getz, Gad
    Hammerman, Peter S.
    Hayes, D. Neil
    Hernandez, Bryan
    Herman, James G.
    Heymach, John V.
    Jurisica, Igor
    Kucherlapati, Raju
    Kwiatkowski, David
    Ladanyi, Marc
    Robertson, Gordon
    Schultz, Nikolaus
    Shen, Ronglai
    Sinha, Rileen
    Sougnez, Carrie
    Tsao, Ming-Sound
    Travis, William D.
    Weinstein, John N.
    Wigle, Dennis A.
    Wilkerson, Matthew D.
    Chu, Andy
    Cherniack, Andrew D.
    Hadjipanayis, Angela
    Rosenberg, Mara
    Weisenberger, Daniel J.
    Laird, Peter W.
    Radenbaugh, Amie
    Ma, Singer
    Stuart, Joshua M.
    Byers, Lauren Averett
    Baylin, Stephen B.
    Govindan, Ramaswamy
    Meyerson, Matthew
    Rosenberg, Mara
    Gabriel, Stacey B.
    Cibulskis, Kristian
    Sougnez, Carrie
    Kim, Jaegil
    Stewart, Chip
    [J]. NATURE, 2014, 511 (7511) : 543 - 550
  • [8] Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
    Ding, Qingjie
    Zhang, Zhuming
    Liu, Jin-Jun
    Jiang, Nan
    Zhang, Jing
    Ross, Tina M.
    Chu, Xin-Jie
    Bartkovitz, David
    Podlaski, Frank
    Janson, Cheryl
    Tovar, Christian
    Filipovic, Zoran M.
    Higgins, Brian
    Glenn, Kelli
    Packman, Kathryn
    Vassilev, Lyubomir T.
    Graves, Bradford
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (14) : 5979 - 5983
  • [9] Bias in meta-analysis detected by a simple, graphical test
    Egger, M
    Smith, GD
    Schneider, M
    Minder, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109): : 629 - 634
  • [10] K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer
    Fukuyama, Y
    Mitsudomi, T
    Sugio, K
    Ishida, T
    Akazawa, K
    Sugimachi, K
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (08) : 1125 - 1130